Blood Test for Lung Cancer
(PROACT-LUNG Trial)
Trial Summary
What is the purpose of this trial?
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Research Team
Victoria Sumner
Principal Investigator
Freenome Holdings Inc.
Eligibility Criteria
This trial is for people aged 50 or older who are current or former smokers with a history of smoking at least 20 packs a year. Participants must understand and agree to sign consent forms.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Blood Sample Collection
Blood samples are collected from participants for the Freenome Multiomics Blood Test
Standard-of-Care Screening
Participants undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT)
Follow-up
Participants are monitored for safety and effectiveness after screening, with data collection on diagnostic tests and procedures related to lung cancer diagnosis
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Freenome Holdings Inc.
Lead Sponsor